EUVIMEDEUVIMED entdecken
Crossref

Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy

Esmail Jafari, Reyhaneh Manafi-Farid, Hojjat Ahmadzadehfar, Fatemeh Salek, Narges Jokar, Ahmad Keshavarz, GhasemAli Divband, Habibollah Dadgar, Farshad Zohrabi, Majid Assadi

Nuklearmedizin - NuclearMedicine · 01.12.2024 · 63 (06) · 347-358

DOI: 10.1055/a-2365-8113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.12.2024. Verfasst von Esmail Jafari und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Persian Gulf Nuclear Medicine Research Center, Department of Nuclear Medicine, Molecular Imaging, and Theranostics, Bushehr Medical University Ho…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Gallium Radioisotopes, Gallium Isotopes, Prostate-Specific Antigen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In this study, we sought to identify the clinical baseline characteristics and pre-therapy 68Ga-PSMA PET derived parameters that can have impact on PSA (biochemical) response, OS and PSA PFS in patients with metastatic castration-resistant prostate cancer (mCRPC) who undergo RLT with [177Lu]Lu-PSMA-617.

Methods

Various pre-treatment clinical and PSMA PET derived parameters were gathered and computed. We used PSA response as the criteria for more than a 50% decrease in PSA level, and OS and PSA PFS as endpoints. We assessed the collected parameters in relation to PSA response. Additionally, we employed univariable Cox regression and Kaplan-Meier analysis with log rank to evaluate the influence of the parameters on OS and PFS.

Results

A total of 125 mCRPC patients were included in this study. The median age was 68 years (range: 49–89). Among the cases, 77 patients (62%) showed PSARS, while 48 patients (38%) did not show PSA response. The median OS was 14 months (range: 1–60), and the median PSA-PFS was 10 months (range: 1–56). Age, prior history of chemotherapy, and SUVmax had a significant impact on PSA response (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantGallium RadioisotopesGallium IsotopesProstate-Specific AntigenLutetiumDipeptidesNeoplasm MetastasisHeterocyclic Compounds, 1-RingHumansMaleAgedMiddle AgedAged, 80 and overPrognosisTreatment OutcomeEdetic AcidPositron-Emission TomographyProgression-Free SurvivalRadioisotopesRetrospective StudiesPositron Emission Tomography Computed TomographyRadiopharmaceuticals

Substanzen

Gallium RadioisotopesGallium IsotopesProstate-Specific AntigenLutetiumgallium 68 PSMA-11DipeptidesHeterocyclic Compounds, 1-RingPluvictoEdetic AcidRadioisotopes

Autor:innen und Institutionen

  • The Persian Gulf Nuclear Medicine Research Center, Department of Nuclear Medicine, Molecular Imaging, and Theranostics, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bu…
  • Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Nuclear Medicine, Klinikum Westfalen, Dortmund, Germany.
  • IoT and Signal Processing Research Group, ICT Research Institute, Faculty of Intelligent Systems Engineering and Data Science, Persian Gulf University, Bushehr, Iran.
  • Department of Nuclear Medicine, Jam Hospital, Tehran, Iran.
  • Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran.

Zitieren

APA

Jafari, E., Manafi-Farid, R., Ahmadzadehfar, H., Salek, F., Jokar, N., Keshavarz, A., Divband, G., Dadgar, H., Zohrabi, F., & Assadi, M. (2024). Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy. Nuklearmedizin - NuclearMedicine, 63(06), 347-358. https://doi.org/10.1055/a-2365-8113

Vancouver

Jafari E, Manafi-Farid R, Ahmadzadehfar H, Salek F, Jokar N, Keshavarz A, et al. Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy. Nuklearmedizin - NuclearMedicine. 2024;63(06):347-358. doi:10.1055/a-2365-8113

BibTeX
@article{Jafari2024,
  author = {Jafari, Esmail and Manafi-Farid, Reyhaneh and Ahmadzadehfar, Hojjat and Salek, Fatemeh and Jokar, Narges and Keshavarz, Ahmad and Divband, GhasemAli and Dadgar, Habibollah and Zohrabi, Farshad and Assadi, Majid},
  title = {Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2024},
  volume = {63},
  number = {06},
  pages = {347--358},
  doi = {10.1055/a-2365-8113}
}
Kostenlos starten →